Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review synthesizes recent molecular and preclinical advances in alopecia areata and androgenetic alopecia, highlighting how interventions targeting specific intracellular signaling pathways and utilizing stem cell technologies can support precision regrowth and structural follicle reconstruction.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This review highlights the potential of rosemary as a treatment for various types of alopecia, with effects possibly comparable to minoxidil and a favorable safety profile, though further large-scale studies are necessary to confirm these findings.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

The document suggests a bacteria plays a significant role in acne rosacea and that white hair can regain color after transplant, meriting more research on reversing grey hair.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

JAK inhibitors are generally safe for treating alopecia areata.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.